FDA approves Cleviprex for hypertension
The FDA has approved Cleviprex (clevidipine butyrate, from The Medicines Company), an IV calcium channel blocker, for the reduction of blood pressure when oral therapy is not feasible or desirable.
Cleviprex has a rapid onset and offset of action and can be titrated for precise blood pressure control. Unlike many current IV antihypertensive agents, Cleviprex is metabolized in the blood and tissues and does not accumulate in the body.
For more information call (800) 388-1183 or visit www.cleviprex.com.